Australia markets open in 3 hours 42 minutes

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
39.27+0.53 (+1.37%)
As of 02:16PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close38.74
Open38.89
Bid39.13 x 2200
Ask39.20 x 1100
Day's range38.26 - 39.46
52-week range27.99 - 43.75
Volume484,092
Avg. volume591,930
Market cap2.902B
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares. The common shares were offered at a public offering

  • GlobeNewswire

    Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

    VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “Xenon will have another strong presence at AES this year, with many presentations and activities aimed at raising awareness about our XEN1101

  • GlobeNewswire

    Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

    VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company, today announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 769,230 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $32.50